Free Trial

Ovid Therapeutics (OVID) Competitors

Ovid Therapeutics logo
$0.40 -0.01 (-3.34%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$0.41 +0.01 (+1.98%)
As of 07/11/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OVID vs. CRBP, OKYO, CHRS, WHWK, VIRI, MGNX, OCX, ZNTL, FBRX, and BYSI

Should you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include Corbus Pharmaceuticals (CRBP), OKYO Pharma (OKYO), Coherus Oncology (CHRS), Whitehawk Therapeutics (WHWK), Virios Therapeutics (VIRI), MacroGenics (MGNX), OncoCyte (OCX), Zentalis Pharmaceuticals (ZNTL), Forte Biosciences (FBRX), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry.

Ovid Therapeutics vs. Its Competitors

Ovid Therapeutics (NASDAQ:OVID) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 13.1% of Ovid Therapeutics shares are held by insiders. Comparatively, 3.6% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ovid Therapeutics currently has a consensus target price of $3.13, indicating a potential upside of 671.60%. Corbus Pharmaceuticals has a consensus target price of $50.88, indicating a potential upside of 515.18%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Corbus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ovid Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Corbus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.10

Ovid Therapeutics has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ovid Therapeutics$570K50.53-$26.43M-$0.35-1.16
Corbus PharmaceuticalsN/AN/A-$40.21M-$4.22-1.96

Corbus Pharmaceuticals has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -4,562.23%. Ovid Therapeutics' return on equity of -34.17% beat Corbus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ovid Therapeutics-4,562.23% -34.17% -25.34%
Corbus Pharmaceuticals N/A -36.87%-32.87%

Ovid Therapeutics has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 3.05, meaning that its share price is 205% more volatile than the S&P 500.

In the previous week, Ovid Therapeutics had 1 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 3 mentions for Ovid Therapeutics and 2 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.51 beat Ovid Therapeutics' score of 0.92 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ovid Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Corbus Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Ovid Therapeutics beats Corbus Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get Ovid Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OVID vs. The Competition

MetricOvid TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$29.80M$2.97B$5.62B$9.09B
Dividend YieldN/A2.39%5.24%4.00%
P/E Ratio-1.1620.7128.1320.27
Price / Sales50.53288.27428.2698.57
Price / CashN/A42.8637.4658.16
Price / Book0.427.638.045.49
Net Income-$26.43M-$55.05M$3.18B$250.45M
7 Day Performance17.73%8.43%3.62%4.79%
1 Month Performance39.99%5.42%4.06%7.68%
1 Year Performance-57.52%2.03%30.01%16.43%

Ovid Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OVID
Ovid Therapeutics
4.7292 of 5 stars
$0.41
-3.3%
$3.13
+671.6%
-57.3%$29.80M$570K-1.1660Gap Up
CRBP
Corbus Pharmaceuticals
4.4637 of 5 stars
$7.30
-5.3%
$50.88
+596.9%
-84.5%$94.35MN/A-1.7340Positive News
OKYO
OKYO Pharma
3.239 of 5 stars
$2.82
+1.4%
$7.00
+148.2%
+91.2%$94.07MN/A0.007Gap Up
CHRS
Coherus Oncology
3.8087 of 5 stars
$0.75
-7.9%
$4.68
+527.6%
-45.3%$93.91M$266.96M-0.66330News Coverage
WHWK
Whitehawk Therapeutics
N/A$1.98
-0.5%
N/AN/A$93.75M$25.98M0.0040Positive News
VIRI
Virios Therapeutics
N/A$4.80
-0.6%
$5.00
+4.2%
+1,936.7%$92.44MN/A-17.785
MGNX
MacroGenics
4.2583 of 5 stars
$1.36
-6.8%
$5.71
+320.2%
-65.4%$92.11M$149.96M-1.53430News Coverage
Analyst Upgrade
OCX
OncoCyte
1.9182 of 5 stars
$3.18
+16.3%
$6.06
+90.9%
+0.8%$90.80M$3.84M-0.90120
ZNTL
Zentalis Pharmaceuticals
2.2574 of 5 stars
$1.19
-5.6%
$8.37
+603.1%
-66.6%$90.66M$67.43M-0.38160News Coverage
FBRX
Forte Biosciences
3.5382 of 5 stars
$12.65
-7.4%
$61.00
+382.2%
+40,918.7%$89.93MN/A-0.785Positive News
Options Volume
Gap Down
BYSI
BeyondSpring
N/A$2.27
+1.8%
N/A+1.8%$89.90M$1.75M0.0080Gap Up

Related Companies and Tools


This page (NASDAQ:OVID) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners